Oxford, UK – 27 August 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2015. Read More
Oxford, UK – 6 August 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2015 on Thursday 27 August 2015… Read More
Oxford, UK – 23 June 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will present today at the 2015 JMP Securities Life… Read More
Oxford, UK – 29 May 2015: Oxford BioMedica plc (LSE:OXB) (“the Group”), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, is scheduled to present at the Jefferies 2015… Read More
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a Non-Executive Director of the Group. Read More
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group” or “Oxford Biomedica”) (LSE:OXB), a leading gene and cell therapy Group, today publishes its interim management statement for the period from 1 January to… Read More
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene and cell therapy based biopharmaceutical company, today announces that results from the 21 patients in its Phase I study of RetinoStat… Read More
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE:OXB) (“the Group”), a leading gene and cell therapy group, today announces that Professor Stéphane Palfi MD, PhD has presented a summary of the results from the 12 months and long… Read More
Oxford, UK – 1 May 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford BioMedica” or the “Group”) a leading gene and cell therapy Group, today announces that it has secured a $50 million loan facility from a subsidiary of Oberland… Read More
London, UK – 2 April 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the 2014 Annual Report and Accounts and the Notice of Annual… Read More
London, UK – 20 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief Development Officer, will present at the 3… Read More
You have selected Encore.Encore is InterCall’s recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen… Read More